aspartyl-alanyl-diketopiperazine

Aspartyl-alanyl-diketopiperazine (DA-DKP) is a cyclic dipeptide derived from the N-terminus of human serum albumin (HSA). It is the primary active component of Ampion, a drug candidate developed by Ampio Pharmaceuticals. DA-DKP exhibits immunomodulatory and anti-inflammatory effects by inhibiting T-cell activation and reducing the secretion of pro-inflammatory cytokines such as TNF-alpha and IFN-gamma. Its mechanism of action involves the modulation of signaling pathways, potentially through interaction with the CXCR4 receptor. Ampion has been investigated in Phase 3 clinical trials for the treatment of pain associated with severe osteoarthritis of the knee, administered via intra-articular injection. It has also been explored for respiratory distress in COVID-19 patients via inhalation and intravenous routes, as well as for Long COVID and hand osteoarthritis. However, Ampio Pharmaceuticals announced the cessation of all clinical development for Ampion in 2023.

Brand names

Ampion

Other names

DA-DKPD-alanyl-L-aspartyl-diketopiperazine3-methyl-2,5-diketopiperazine-6-acetic acid